9 min listen
Finally, a new medicine for Alzheimer’s disease
Finally, a new medicine for Alzheimer’s disease
ratings:
Length:
9 minutes
Released:
Jun 10, 2021
Format:
Podcast episode
Description
The FDA’s accelerated approval of Biogen Inc.’s Alzheimer’s disease therapy, Aduhelm (aducanumab), is the first real beacon of hope in 18 years for the 50 million people living with the disease. But the approval was met with controversy over the drug’s efficacy and pricing. Even as Biogen readies to launch in just two weeks with more than 900 sites lined up to start treating patients, a required confirmatory study could sink everything.BioWorld has been reporting on the development of Aduhelm since its discovery, by way of Neurimmune AG’s reverse translational medicine technology. Later licensed to Biogen, it was co-developed with Eisai Co. Ltd.In this episode, News Editor Michael Fitzhugh talks with Ivana Rubino, Biogen’s VP of global and U.S. medical affairs for Alzheimer’s disease, about the approval, the controversies and what it all means for Biogen’s future. Hosted on Acast. See acast.com/privacy for more information.
Released:
Jun 10, 2021
Format:
Podcast episode
Titles in the series (36)
Finally, a new medicine for Alzheimer’s disease: One-on-one with Biogen’s Ivana Rubino by The BioWorld Insider Podcast